OCT 30, 2014 10:30 AM PDT

Therapeutic Drug Monitoring (TDM) in Cancer Chemotherapy: A Tool for Optimizing Drug Management

Speaker
  • Associate Professor of Pathology, Clinical Toxicology, Director, Point-of-Care Testing, Johns Hopkins University School of Medicine
    Biography
      Dr. William Clarke is an associate professor of pathology at the Johns Hopkins University School of Medicine. His research focuses on the development of analytical methods for drug analysis, clinical mass spectrometry, and devices for point-of-care testing. Dr. Clarke serves as the director of Clinical Toxicology as well as Critical and Point-of-Care Testing Program at The Johns Hopkins Hospital.

      His team's current projects include qualitative screening for antiretroviral drugs and substances of abuse in various HIV- prevention clinical trials, development and validation of mass spectrometry methods for clinical analysis, and development of clinical assays for use on microfluidic platforms.

      Dr. Clarke received his B.S. in Chemistry from the University of Nebraska at Kearney and his Ph.D. in Analytical Chemistry from the University of Nebraska-Lincoln, as well as an M.B.A. from the Carey School of Business at Johns Hopkins University. He completed a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine.

    Abstract

    Many drugs currently used for anti-cancer therapy demonstrate significant inter-individual variability that cannot be normalized using body weight or body surface area. There is an increasing amount of evidence in the scientific literature describing the use of therapeutic drug monitoring (TDM) to inform dosing of these drugs can lead to more effective treatment. This presentation will discuss the scientific literature addressing inter-individual variability of these drugs, the concept of maximum tolerated dose (MTD), and why an approach using maximum tolerated exposure (MTE) might be a better way to manage some chemotherapeutic drugs. Specific examples of TDM in oncology will be discussed including 5-fluorouracil, taxanes, and tyrosine kinase inhibitors.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    Loading Comments...
    Show Resources